+5.2%
PDD vs MRNA
-27.3%
+32.5%
-68.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 5y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.7% | -2.2% | -0.5% | -2.5% |
| 7D | +6.0% | -12.7% | +18.7% | +7.3% |
| 30D | +6.3% | -20.7% | +27.0% | +8.1% |
| 3M | -6.5% | +46.3% | -52.8% | -10.7% |
| 6M | -14.7% | +305.2% | -320.0% | -35.2% |
| YTD | -26.2% | +561.2% | -587.4% | -51.6% |
| 1Y | -25.9% | +772.1% | -798.0% | -55.0% |
| 3Y | -29.6% | +147.0% | -176.5% | -46.8% |
| All | +5.2% | -27.3% | +32.5% | -9.0% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 5y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
5y analysis · Full analysis span regression · 6 months rolling